|
|
Post by kite on Apr 30, 2019 8:01:52 GMT -5
|
|
|
|
Post by tw12 on Apr 30, 2019 8:07:25 GMT -5
Three days earlier than planned...
|
|
|
|
Post by mnkdfann on Apr 30, 2019 8:24:02 GMT -5
Three days earlier than planned... Are you saying Mannkind previously announced this would be three days later? If it did, I missed it. Or is the announced date just different from what some people were expecting / predicting? |
|
|
|
Post by sportsrancho on Apr 30, 2019 9:14:35 GMT -5
Three days earlier than planned... Are you saying Mannkind previously announced this would be three days later? If it did, I missed it. Or is the announced date just different from what some people were expecting / predicting? I’d like to know also who knew the first date? |
|
|
|
Post by mannmade on Apr 30, 2019 9:27:04 GMT -5
Speaking of financials I beleive DF will be paid off this May and July and the only remaining Long Term Debt will be to the Mann Foundation. Now to see how it is paid... Stock or cash? Likely the returned shares from the $2.38 warrants will be used is my guess.
|
|
|
|
Post by awesomo on Apr 30, 2019 10:14:31 GMT -5
Three days earlier than predicted, there was never a previously announced date.
At least the earnings call is before the ASM so investors can potentially address issues.
|
|
|
|
Post by tw12 on Apr 30, 2019 11:35:44 GMT -5
From the Etrade site, current today:
April 30, 2019 12:34 PM ET
NASDAQ
MNKD MANNKIND CORP COM NEW
Healthcare : Biotechnology & Medical Research
Q1 earnings are expected to be announced on 5/10/19 Estimates: -0.070 | -0.100 | -0.130 (High | Mean | Low)
|
|
|
|
Post by awesomo on Apr 30, 2019 11:52:52 GMT -5
"Expected to be" is just basing the date off past years, it is just an estimate. It doesn't mean anything.
|
|
|
|
Post by wyattdog on Apr 30, 2019 12:08:26 GMT -5
|
|
|
|
Post by mytakeonit on Apr 30, 2019 13:46:24 GMT -5
From the Etrade site, current today: April 30, 2019 12:34 PM ET
NASDAQ
MNKD MANNKIND CORP COM NEW
Healthcare : Biotechnology & Medical Research
Q1 earnings are expected to be announced on 5/10/19 Estimates: -0.070 | -0.100 | -0.130 (High | Mean | Low)Hmm ... I saw this also. HEY no wonder it was wrong !!! It was an estimate from E*Trade, the same broker that finally made available TODAY monies that I requested for trading on 4/20/19!!! And it only took 2 tries to make it happen !!! Remarkable ! www.youtube.com/watch?v=o9PeXUsdFys |
|
|
|
Post by cretin11 on May 1, 2019 16:52:04 GMT -5
E*Trade saved you money with that delay, now you get a lower price point!
|
|
|
|
Post by mytakeonit on May 1, 2019 19:16:39 GMT -5
NO NO NO ... I hate when my pps goes down too fast. I get nose bleed !!!
But, that's mytakeonit
|
|
|
|
Post by sportsrancho on May 6, 2019 6:05:22 GMT -5
MannKind logoMannKind (NASDAQ:MNKD) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.11. The business had revenue of $16.03 million for the quarter, compared to the consensus estimate of $5.20 million. During the same period last year, the firm earned ($0.28) earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Get MannKind alerts: MNKD opened at $1.53 on Friday. MannKind has a fifty-two week low of $0.94 and a fifty-two week high of $3.04. A number of equities research analysts recently weighed in on MNKD shares. BidaskClub raised shares of MannKind from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. Svb Leerink started coverage on shares of MannKind in a research note on Monday, March 4th. They set an “outperform” rating and a $3.00 price target for the company. Finally, Leerink Swann started coverage on shares of MannKind in a research note on Monday, March 4th. They set an “outperform” rating and a $3.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. MannKind presently has an average rating of “Hold” and a consensus target price of $3.06. A hedge fund recently raised its stake in MannKind stock. Geode Capital Management LLC increased its holdings in shares of MannKind Co. (NASDAQ:MNKD) by 13.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,666,104 shares of the biopharmaceutical company’s stock after buying an additional 202,865 shares during the period. Geode Capital Management LLC owned 1.04% of MannKind worth $1,766,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.01% of the company’s stock. www.thelincolnianonline.com/2019/05/05/mannkind-mnkd-set-to-announce-quarterly-earnings-on-tuesday.html |
|
|
|
Post by winner on May 7, 2019 5:20:51 GMT -5
Looking forward to reading the Q1 release.
|
|
|
|
Post by morfu on May 7, 2019 6:15:39 GMT -5
MannKind logoMannKind (NASDAQ:MNKD) is scheduled to announce its earnings results before the market opens on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. MannKind (NASDAQ:MNKD) last posted its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.17) by $0.11. The business had revenue of $16.03 million for the quarter, compared to the consensus estimate of $5.20 million. During the same period last year, the firm earned ($0.28) earnings per share. On average, analysts expect MannKind to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. Get MannKind alerts: MNKD opened at $1.53 on Friday. MannKind has a fifty-two week low of $0.94 and a fifty-two week high of $3.04. A number of equities research analysts recently weighed in on MNKD shares. BidaskClub raised shares of MannKind from a “hold” rating to a “buy” rating in a research note on Thursday, March 14th. Svb Leerink started coverage on shares of MannKind in a research note on Monday, March 4th. They set an “outperform” rating and a $3.00 price target for the company. Finally, Leerink Swann started coverage on shares of MannKind in a research note on Monday, March 4th. They set an “outperform” rating and a $3.00 price target for the company. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. MannKind presently has an average rating of “Hold” and a consensus target price of $3.06. A hedge fund recently raised its stake in MannKind stock. Geode Capital Management LLC increased its holdings in shares of MannKind Co. (NASDAQ:MNKD) by 13.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,666,104 shares of the biopharmaceutical company’s stock after buying an additional 202,865 shares during the period. Geode Capital Management LLC owned 1.04% of MannKind worth $1,766,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 30.01% of the company’s stock. www.thelincolnianonline.com/2019/05/05/mannkind-mnkd-set-to-announce-quarterly-earnings-on-tuesday.htmlThank you for posting this, but I feel obliged to point out my usual criticism, that an target of 3$ without any time frame is more than useless. If Afrezza ( or any other Mannkind product for that matter) succeeds in selling with a profit, the company will be worth a lot more than the roughly 700Mil$ this target indicates. If not, well then it seems awfully high.. In short this target is not worth anything, no information here!
|
|
